Business Context and Reporting Period
This Form 8-K Current Report was filed by Predictive Oncology Inc. on March 14, 2025 (with a signature date of March 20, 2025). The filing discloses the entry into a Material Definitive Agreement regarding the divestiture of a specific business segment.
Key Financial Metrics and Transaction Details
The filing details an asset purchase agreement with DeRoyal Industries, Inc. to sell the Company's business related to automated, direct-to-drain medical fluid disposal (the "STREAMWAY" product line). This business was operated by the wholly-owned subsidiary, Skyline Medical Inc., and reported within the Eagan operating segment.
- Total Purchase Price: $625,000.
- Assets Transferred: Inventories, prototypes, equipment, intellectual property (trademarks, patents), customer contracts, permits, and cash/accounts receivable due within 90 days.
- Liabilities Assumed by Buyer: Lease obligations for office/warehouse space in Eagan, MN; accounts payable due within 90 days; and contract liabilities associated with the Business.
Note: This filing does not provide consolidated revenue, profit, cash flow, margins, or total debt figures for the Company.
Material Changes
The primary material change is the divestiture of the Skyline Medical Inc. business unit. This transaction removes the STREAMWAY product line and its associated assets and liabilities from Predictive Oncology Inc.'s balance sheet and operations effective March 14, 2025.
Outlook, Risks, and Management Commentary
The filing includes standard post-closing covenants customary for such transactions. No specific forward-looking guidance, risk factors, or management commentary regarding future financial performance is provided in this specific 8-K text, other than the confirmation of the transaction closure.
Investor Verification Checklist
- Verify the impact of the $625,000 sale price on the Company's current cash position and potential gain/loss on disposal in the next quarterly report.
- Confirm the extent to which the Eagan reportable segment's future revenue will be affected by the removal of the STREAMWAY product line.
- Review the full Asset Purchase Agreement (Exhibit 10.1) for details on retained liabilities or contingent obligations not assumed by DeRoyal.
- Check subsequent filings for the updated segment reporting structure following the divestiture.